Drug Type Antibody drug conjugate (ADC) |
Synonyms GSK5764227, GSK’227, HS 20093 + [1] |
Target |
Mechanism CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (US), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 3 | - | 30 Sep 2024 | |
Small cell lung cancer recurrent | Phase 3 | CN | 04 Jul 2024 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | CN | 01 Mar 2024 | |
Esophageal Carcinoma | Phase 2 | CN | 25 Jan 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 13 Dec 2023 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 13 Dec 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | CN | 04 Dec 2023 | |
Refractory Osteosarcoma | Phase 2 | CN | 08 Jun 2023 | |
Colorectal Cancer | Phase 1 | CN | 17 Oct 2024 | |
Soft Tissue Sarcoma | IND Approval | CN | 22 Oct 2024 |
Phase 1 | 56 | (8.0 mg/kg Q3W) | gttfpaxwxm(nakfahdwnt) = bdsyrampyi lsyyxaalgf (stcpkhgtit ) View more | Positive | 24 May 2024 | ||
(10.0 mg/kg Q3W) | gttfpaxwxm(nakfahdwnt) = dahsszvvgi lsyyxaalgf (stcpkhgtit ) View more | ||||||
Phase 2 | Osteosarcoma, Recurrent Last line | 34 | woxhlswuxm(tczuyboiuy) = ebuvqfpwup vpqrkgklmk (pdafimctjm ) View more | Positive | 24 May 2024 | ||
(8.0 mg/kg) | ilspwodkdw(snaxsoyfwx) = qyvzwiaefs hgsfjxwmno (iegylcwmjg ) | ||||||
Phase 1 | 53 | xqkxfinxpc(pinequviql) = xgjtpzlpfg qdtkbruxln (mhdocbdrku ) View more | Positive | 31 May 2023 | |||
(SCLC) | aqkxujlypv(csrvyzmhni) = eejihjdncl vdkrpdodpl (wxltflgiod ) View more |